Myc-driven murine prostate cancer shares molecular features with human prostate tumors

Cancer Cell

Volumn 4, Issue 3, 2003, Pages 223-238

  Ellwood Yen, Katharine ^a,c   Graeber, Thomas G ^a,b   Wongvipat, John ^a,c   Iruela Arispe, M Luisa ^a   Zhang, JianFeng ^d,e   Matusik, Robert ^d   Thomas, George V ^a   Sawyers, Charles L ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOTRANSFERASE; PROTEIN KINASE PIM 1; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CANCER INVASION; CANCER RESEARCH; CARCINOGENESIS; CONTROLLED STUDY; DATA BASE; GENE EXPRESSION; GENE FUNCTION; GENE INTERACTION; MOLECULAR MECHANICS; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE MYC; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE TUMOR; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0141569009     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00197-1     Document Type: Article

References (58)

1. Abdulkadir S.A., Magee J.A., Peters T.J., Kaleem Z., Naughton C.K., Humphrey P.A., Milbrandt J. Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol. Cell. Biol. 22:2002;1495-1503.
2. Ahmed N.N., Grimes H.L., Bellacosa A., Chan T.O., Tsichlis P.N. Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc. Natl. Acad. Sci. USA. 94:1997;3627-3632.
3. Amati B., Alevizopoulos K., Vlach J. Myc and the cell cycle. Front. Biosci. 3:1998;D250-D268.
4. Bhatia-Gaur R., Donjacour A.A., Sciavolino P.J., Kim M., Desai N., Young P., Norton C.R., Gridley T., Cardiff R.D., Cunha G.R.et al. Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 13:1999;966-977.
5. Bowen C., Bubendorf L., Voeller H.J., Slack R., Willi N., Sauter G., Gasser T.C., Koivisto P., Lack E.E., Kononen J.et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res. 60:2000;6111-6115.
6. Bubendorf L., Kononen J., Koivisto P., Schraml P., Moch H., Gasser T.C., Willi N., Mihatsch M.J., Sauter G., Kallioniemi O.P. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res. 59:1999;803-806.
7. Coller H.A., Grandori C., Tamayo P., Colbert T., Lander E.S., Eisenman R.N., Golub T.R. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc. Natl. Acad. Sci. USA. 97:2000;3260-3265.
8. Dang C.V. Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol. 19:1999;1-11.
9. Dhanasekaran S.M., Barrette T.R., Ghosh D., Shah R., Varambally S., Kurachi K., Pienta K.J., Rubin M.A., Chinnaiyan A.M. Delineation of prognostic biomarkers in prostate cancer. Nature. 412:2001;822-826.
10. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA. 95:1998;14863-14868.
11. Elenbaas B., Spirio L., Koerner F., Fleming M.D., Zimonjic D.B., Donaher J.L., Popescu N.C., Hahn W.C., Weinberg R.A. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 15:2001;50-65.
12. Elo J.P., Visakorpi T. Molecular genetics of prostate cancer. Ann. Med. 33:2001;130-141.
13. Evan G.I., Wyllie A.H., Gilbert C.S., Littlewood T.D., Land H., Brooks M., Waters C.M., Penn L.Z., Hancock D.C. Induction of apoptosis in fibroblasts by Myc protein. Cell. 69:1992;119-128.
14. Garabedian E.M., Humphrey P.A., Gordon J.I. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proc. Natl. Acad. Sci. USA. 95:1998;15382-15387.
15. Gartel A.L., Shchors K. Mechanisms of Myc-mediated transcriptional repression of growth arrest genes. Exp. Cell Res. 283:2003;17-21.
16. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., Coller H., Loh M.L., Downing J.R., Caligiuri M.A.et al. Molecular classification of cancer. class discovery and class prediction by gene expression monitoring Science. 286:1999;531-537.
17. Greenberg N.M., DeMayo F., Finegold M.J., Medina D., Tilley W.D., Aspinall J.O., Cunha G.R., Donjacour A.A., Matusik R.J., Rosen J.M. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA. 92:1995;3439-3443.
18. He W.W., Sciavolino P.J., Wing J., Augustus M., Hudson P., Meissner P.S., Curtis R.T., Shell B.K., Bostwick D.G., Tindall D.J.et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics. 43:1997;69-77.
19. Hurlin P.J., Foley K.P., Ayer D.E., Eisenman R.N., Hanahan D., Arbeit J.M. Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis. Oncogene. 11:1995;2487-2501.
20. Jain M., Arvanitis C., Chu K., Dewey W., Leonhardt E., Trinh M., Sundberg C.D., Bishop J.M., Felsher D.W. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 297:2002;102-104.
21. Jalkut M.W., Reiter R.E. Role of prostate stem cell antigen in prostate cancer research. Curr. Opin. Urol. 12:2002;401-406.
22. Jenkins R.B., Qian J., Lieber M.M., Bostwick D.G. Detection of Myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res. 57:1997;524-531.
23. Jensen N.A., Pedersen K.M., Lihme F., Rask L., Nielsen J.V., Rasmussen T.E., Mitchelmore C. Astroglial Myc overexpression predisposes mice to primary malignant gliomas. J. Biol. Chem. 278:2002;8300-8308.
24. Karlsson A., Giuriato S., Tang F., Fung-Weier J., Levan G., Felsher D.W. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood. 101:2003;2797-2803.
25. Kasper S., Sheppard P.C., Yan Y., Pettigrew N., Borowsky A.D., Prins G.S., Dodd J.G., Duckworth M.L., Matusik R.J. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice. a model for prostate cancer Lab. Invest. 78:1998;1-9.
26. Kim M.J., Bhatia-Gaur R., Banach-Petrosky W.A., Desai N., Wang Y., Hayward S.W., Cunha G.R., Cardiff R.D., Shen M.M., Abate-Shen C. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res. 62:2002;2999-3004.
27. Kim S.J., Uehara H., Karashima T., Shepherd D.L., Killion J.J., Fidler I.J. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin. Cancer Res. 9:2003;1200-1210.
28. Lam, L.T., Pickeral, O.K., Peng, A.C., Rosenwald, A., Hurt, E.M., Giltnane, J.M., Averett, L.M., Zhao, H., Davis, R.E., Sathyamoorthy, M., et al. (2001). Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol. 2, RESEARCH0041.
29. Lasorella A., Uo T., Iavarone A. Id proteins at the cross-road of development and cancer. Oncogene. 20:2001;8326-8333.
30. Luo Q., Harmon E., Timms B.G., Kretzner L. Novel expression patterns of the myc/max/mad transcription factor network in developing murine prostate gland. J. Urol. 166:2001;1071-1077.
31. Masumori N., Thomas T.Z., Chaurand P., Case T., Paul M., Kasper S., Caprioli R.M., Tsukamoto T., Shappell S.B., Matusik R.J. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res. 61:2001;2239-2249.
32. Moroy T., Verbeek S., Ma A., Achacoso P., Berns A., Alt F. E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice. Oncogene. 6:1991;1941-1948.
33. Nesbit C.E., Tersak J.M., Prochownik E.V. MYC oncogenes and human neoplastic disease. Oncogene. 18:1999;3004-3016.
34. Pelengaris S., Littlewood T., Khan M., Elia G., Evan G. Reversible activation of Myc in skin. induction of a complex neoplastic phenotype by a single oncogenic lesion Mol. Cell. 3:1999;565-577.
35. Pelengaris S., Khan M., Evan G. Myc. more than just a matter of life and death Nat. Rev. Cancer. 2:2002;764-776. a.
36. Pelengaris S., Khan M., Evan G.I. Suppression of myc-induced apoptosis in Beta cells exposes multiple oncogenic properties of myc and triggers carcinogenic progression. Cell. 109:2002;321-334. b.
37. Perez-Stable C., Altman N.H., Mehta P.P., Deftos L.J., Roos B.A. Prostate cancer progression, metastasis, and gene expression in transgenic mice. Cancer Res. 57:1997;900-906.
38. Perou C.M., Jeffrey S.S., van de Rijn M., Rees C.A., Eisen M.B., Ross D.T., Pergamenschikov A., Williams C.F., Zhu S.X., Lee J.C.et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc. Natl. Acad. Sci. USA. 96:1999;9212-9217.
39. Prendergast G.C. Mechanisms of apoptosis by Myc. Oncogene. 18:1999;2967-2987.
40. Qian J., Jenkins R.B., Bostwick D.G. Detection of chromosomal anomalies and Myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization. Mod. Pathol. 10:1997;1113-1119.
41. Rodriguez-Manzaneque J.C., Lane T.F., Ortega M.A., Hynes R.O., Lawler J., Iruela-Arispe M.L. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA. 98:2001;12485-12490.
42. Rosenwald A., Wright G., Wiestner A., Chan W.C., Connors J.M., Campo E., Gascoyne R.D., Grogan T.M., Muller-Hermelink H.K., Smeland E.B.et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 3:2003;185-197.
43. Sato K., Qian J., Slezak J.M., Lieber M.M., Bostwick D.G., Bergstralh E.J., Jenkins R.B. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J. Natl. Cancer Inst. 91:1999;1574-1580.
44. Sears R.C., Nevins J.R. Signaling networks that link cell proliferation and cell fate. J. Biol. Chem. 277:2002;11617-11620.
45. Shibata M.A., Ward J.M., Devor D.E., Liu M.L., Green J.E. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice. histopathological and molecular biological alterations Cancer Res. 56:1996;4894-4903.
46. Singh D., Febbo P.G., Ross K., Jackson D.G., Manola J., Ladd C., Tamayo P., Renshaw A.A., D'Amico A.V., Richie J.P.et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 1:2002;203-209.
47. Thomas R., True L.D., Bassuk J.A., Lange P.H., Vessella R.L. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin. Cancer Res. 6:2000;1140-1149.
48. Tsuchiya N., Slezak J.M., Lieber M.M., Bergstralh E.J., Jenkins R.B. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer. Genes Chromosomes Cancer. 34:2002;363-371.
49. Vaarala M.H., Porvari K., Kyllonen A., Lukkarinen O., Vihko P. The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients. detection of mutated TMPRSS2 form in a case of aggressive disease Int. J. Cancer. 94:2001;705-710.
50. van Lohuizen M., Verbeek S., Krimpenfort P., Domen J., Saris C., Radaszkiewicz T., Berns A. Predisposition to lymphomagenesis in pim-1 transgenic mice. cooperation with Myc and N-myc in murine leukemia virus-induced tumors Cell. 56:1989;673-682.
51. van Lohuizen M., Verbeek S., Scheijen B., Wientjens E., van der Gulden H., Berns A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell. 65:1991;737-752.
52. Voeller H.J., Augustus M., Madike V., Bova G.S., Carter K.C., Gelmann E.P. Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. Cancer Res. 57:1997;4455-4459.
53. Watnick R.S., Cheng Y.N., Rangarajan A., Ince T.A., Weinberg R.A. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell. 3:2003;219-231.
54. Welsh J.B., Sapinoso L.M., Su A.I., Kern S.G., Wang-Rodriguez J., Moskaluk C.A., Frierson H.F. Jr., Hampton G.M. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 61:2001;5974-5978.
55. Whitfield M.L., Sherlock G., Saldanha A.J., Murray J.I., Ball C.A., Alexander K.E., Matese J.C., Perou C.M., Hurt M.M., Brown P.O., Botstein D. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol. Biol. Cell. 13:2002;1977-2000.
56. Wu X., Wu J., Huang J., Powell W.C., Zhang J., Matusik R.J., Sangiorgi F.O., Maxson R.E., Sucov H.M., Roy-Burman P. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech. Dev. 101:2001;61-69.
57. Zhang J., Thomas T.Z., Kasper S., Matusik R.J. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology. 141:2000;4698-4710. a.
58. Zhang X., Lee C., Ng P.Y., Rubin M., Shabsigh A., Buttyan R. Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the Myc oncoprotein. Prostate. 43:2000;278-285. b.